Esophagus Cancer

Esophageal cancer is one of the leading causes of cancer-related deaths worldwide, with approximately 600,000 cases per year globally, making it the seventh most common cancer and the sixth deadliest cancer. At Alfa Cytology, we are committed to helping our clients unravel the complexity of esophageal cancer by providing integrated preclinical research solutions.

Introduction to Esophagus Cancer

Esophageal cancer arises when abnormal cells in the esophagus undergo uncontrolled growth, forming tumors. Esophageal cancer has a poor prognosis due to late diagnosis, with a low 5-year survival rate of 21.6%.

Fig.1 5-Year Relative Survival of Esophageal Cancer. (Credit the National Cancer Institute as the source.)

Types of Esophagus Cancer

There are two main types of esophageal cancer.

• Squamous Cell Carcinoma: Squamous cell carcinoma typically affects the upper and middle parts of the esophagus;
• Adenocarcinoma: Adenocarcinoma occurs in the lower part, near the junction with the stomach.

Therapy Development for Esophagus Cancer

The prevalence of esophageal cancer has indeed been increasing, leading to a greater demand for effective treatment options. This rise in prevalence has spurred considerable research and development efforts in the field, with numerous participants actively working on the development of potential therapies. As of now, there are over 80 active participants involved in the development of more than 90 pipeline therapies specifically targeting esophageal cancer.

The increasing prevalence of esophageal cancer has stimulated a significant research and development effort, with numerous participants actively working on the development of pipeline therapies. Continued research and collaborations are vital to advancing these therapies and ultimately providing more effective therapeutic options for individuals affected by esophageal cancer.

Our Services

At Alfa Cytology, our mission is to make a significant impact in the fight against esophageal cancer by providing comprehensive and state-of-the-art services. We are dedicated to staying at the forefront of innovation and excellence, offering advanced technologies and methodologies in our diagnostic, therapeutic, and monitoring approaches.

Our services include but are not limited to:

Diagnostic Development Platform

Cancer Biomarker Discovery
Imaging Services
Multi-omics Services

Cancer Modeling Platform

Advanced Cellular Models
3D Tumor Modeling
PDX Model
CDX Model
Syngeneic Tumor Model

Therapeutic Development Platform

Small Molecule Drug
Cell Therapy
Gene Therapy

Antibody
Therapeutic Peptide
Cancer Vaccine

At Alfa Cytology, we are committed to being at the forefront of esophageal cancer research and development, offering comprehensive and cutting-edge solutions for the management of this challenging disease. Our dedicated team of experts, state-of-the-art facilities, and extensive experience in preclinical studies, biomarker discovery, and clinical trials enable us to provide invaluable services to our clients.

If you would like more information about our esophageal cancer research and development initiatives, or if you have any inquiries about our comprehensive services, please don't hesitate to contact us.

For research use only.